Skip to main content

First Trust Nasdaq Pharmaceuticals ETF (FTXH)

NASDAQ: FTXH · IEX Real-Time Price · USD
25.86
-0.01 (-0.05%)
After-hours:Oct 15, 2021 4:00 PM EDT
25.87
0.12 (0.48%)
At close: Oct 15, 4:00 PM
Assets$16.78M
NAV$25.82
Expense Ratio0.60%
PE Ratio24.06
Shares Out650,000
Dividend (ttm)$0.23
Dividend Yield0.90%
Ex-Dividend DateSep 23, 2021
1-Year Return
-
Volume5,000
Open26.06
Previous Close25.75
Day's Range25.81 - 26.10
52-Week Low22.71
52-Week High27.01
Beta0.90
Holdings29
Inception DateSep 20, 2016

About FTXH

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.

Asset ClassEquity
SectorLarge Cap
RegionNorth America
IssuerFirst Trust Portfolios
Stock ExchangeNASDAQ
Ticker SymbolFTXH
Index TrackedNasdaq US Smart Pharmaceuticals Index

Top 10 Holdings

59.55% of assets
NameSymbolWeight
Prestige Consumer HealthcarePBH8.38%
MerckMRK8.38%
Johnson & JohnsonJNJ7.63%
PfizerPFE7.47%
AbbVieABBV7.19%
Horizon TherapeuticsHZNP4.31%
AlkermesALKS4.21%
CatalentCTLT4.08%
ZoetisZTS4.04%
Gilead SciencesGILD3.86%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Sep 23, 2021$0.0393Sep 30, 2021
Jun 24, 2021$0.0533Jun 30, 2021
Mar 25, 2021$0.0771Mar 31, 2021
Dec 24, 2020$0.0644Dec 31, 2020
Sep 24, 2020$0.0428Sep 30, 2020
Jun 25, 2020$0.0463Jun 30, 2020
Full Dividend History

News

Pharma ETFs Gain on Q2 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols:IHEPJPPPHXPH
2 months ago - Zacks Investment Research

Pharma ETFs in Focus Post Q1 Earnings

The slew of Q1 results have led to mixed trading in pharma ETFs over the past month.

Other symbols:IHEPJPPPHXPH
5 months ago - Zacks Investment Research

ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.

Other symbols:FDLIEIHIHE
6 months ago - Zacks Investment Research

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Other symbols:IHEPJPPPHXPH
8 months ago - Zacks Investment Research

ETFs to Shine as Pfizer's COVID-19 Vaccine Gets a Nod in Europe

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.

Other symbols:DHSFDLHDVIEIH
9 months ago - Zacks Investment Research

3 Reasons to Bet on Healthcare ETFs

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

Other symbols:PJPPPHPSCHXHSXPH
11 months ago - Zacks Investment Research

Q3 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Other symbols:IHEPJPPPHXPH
11 months ago - Zacks Investment Research

Nasdaq Pharmaceuticals ETF (FTXH) Hits a 52-Week High

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has hit a new 52-week high. Are more gains in store?

1 year ago - Zacks Investment Research

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Other symbols:IHEPJPPPHXPH
1 year ago - Zacks Investment Research

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

1 year ago - Zacks Investment Research

ETF Spotlight: Pharmaceuticals driven higher by Pfizer

CNBC'S Morgan Brennan takes a look at pharmaceutical as Pfizer's positive vaccine news has led the sector higher.

1 year ago - CNBC Television

Pharma ETFs Gain on Healthy Q4 Earnings

Strong results led to solid trading in pharma ETFs over the past week.

Other symbols:IHEPJPPPHXPH
1 year ago - Zacks Investment Research

Pharma ETFs Set to Benefit Post Strong Q3 Earnings

Robust results led to solid trading in pharma ETFs in a month.

Other symbols:IHEPJPPPHXPH
1 year ago - Zacks Investment Research

Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

Despite robust results, pharma ETFs have been trending downward in a month.

Other symbols:IHEPJPPPHXPH
2 years ago - Zacks Investment Research

Pharma ETFs Down Despite Solid Q1 Results

Despite such robust results, pharma ETFs have been trending downward in a month.

Other symbols:IHEPJPPPHXPH
2 years ago - Zacks Investment Research